Immunotherapy and immunoevasion of colorectal cancer

Mohammad Al Zein; Mona Boukhdoud; Hadi Shammaa; Hadi Mouslem; Lemir Majed El Ayoubi; Rabah Iratni; Khodr Issa; Maha Khachab; Hazem I. Assi; Amirhossein Sahebkar; Ali H. Eid

doi:10.1016/j.drudis.2023.103669

Immunotherapy and immunoevasion of colorectal cancer

Mohammad Al Zein
, Mona Boukhdoud
, Hadi Shammaa
, Hadi Mouslem
, Lemir Majed El Ayoubi
, Rabah Iratni
, Khodr Issa
, Maha Khachab
, Hazem I. Assi
, Amirhossein Sahebkar
, Ali H. Eid

Research output: Contribution to journal › Review article › peer-review

80 Citations (Scopus)

Abstract

The tremendous success of immunotherapy in clinical trials has led to its establishment as a new pillar of cancer therapy. However, little clinical efficacy has been achieved in microsatellite stable colorectal cancer (MSS-CRC), which constitutes most CRC tumors. Here, we discuss the molecular and genetic heterogeneity of CRC. We review the immune escape mechanisms, and focus on the latest advances in immunotherapy as a treatment modality for CRC. By providing a better understanding of the tumor microenvironment (TME) and the molecular mechanisms underlying immunoevasion, this review offers an insight into developing therapeutic strategies that are effective for patients with various subsets of CRC.

Original language	English
Article number	103669
Journal	Drug Discovery Today
Volume	28
Issue number	9
DOIs	https://doi.org/10.1016/j.drudis.2023.103669
Publication status	Published - Sept 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

CTLA-4
PD-1
adoptive cell therapy
cancer vaccines
colorectal cancer
immune checkpoint inhibitor

ASJC Scopus subject areas

Pharmacology
Drug Discovery

Access to Document

10.1016/j.drudis.2023.103669

Cite this

@article{6b58033080ab47bda388c5f0d30b50b5,

title = "Immunotherapy and immunoevasion of colorectal cancer",

abstract = "The tremendous success of immunotherapy in clinical trials has led to its establishment as a new pillar of cancer therapy. However, little clinical efficacy has been achieved in microsatellite stable colorectal cancer (MSS-CRC), which constitutes most CRC tumors. Here, we discuss the molecular and genetic heterogeneity of CRC. We review the immune escape mechanisms, and focus on the latest advances in immunotherapy as a treatment modality for CRC. By providing a better understanding of the tumor microenvironment (TME) and the molecular mechanisms underlying immunoevasion, this review offers an insight into developing therapeutic strategies that are effective for patients with various subsets of CRC.",

keywords = "CTLA-4, PD-1, adoptive cell therapy, cancer vaccines, colorectal cancer, immune checkpoint inhibitor",

author = "\{Al Zein\}, Mohammad and Mona Boukhdoud and Hadi Shammaa and Hadi Mouslem and \{El Ayoubi\}, \{Lemir Majed\} and Rabah Iratni and Khodr Issa and Maha Khachab and Assi, \{Hazem I.\} and Amirhossein Sahebkar and Eid, \{Ali H.\}",

note = "Publisher Copyright: {\textcopyright} 2023 Elsevier Ltd",

year = "2023",

month = sep,

doi = "10.1016/j.drudis.2023.103669",

language = "English",

volume = "28",

journal = "Drug Discovery Today",

issn = "1359-6446",

publisher = "Elsevier Ltd",

number = "9",

}

TY - JOUR

T1 - Immunotherapy and immunoevasion of colorectal cancer

AU - Al Zein, Mohammad

AU - Boukhdoud, Mona

AU - Shammaa, Hadi

AU - Mouslem, Hadi

AU - El Ayoubi, Lemir Majed

AU - Iratni, Rabah

AU - Issa, Khodr

AU - Khachab, Maha

AU - Assi, Hazem I.

AU - Sahebkar, Amirhossein

AU - Eid, Ali H.

PY - 2023/9

Y1 - 2023/9

N2 - The tremendous success of immunotherapy in clinical trials has led to its establishment as a new pillar of cancer therapy. However, little clinical efficacy has been achieved in microsatellite stable colorectal cancer (MSS-CRC), which constitutes most CRC tumors. Here, we discuss the molecular and genetic heterogeneity of CRC. We review the immune escape mechanisms, and focus on the latest advances in immunotherapy as a treatment modality for CRC. By providing a better understanding of the tumor microenvironment (TME) and the molecular mechanisms underlying immunoevasion, this review offers an insight into developing therapeutic strategies that are effective for patients with various subsets of CRC.

AB - The tremendous success of immunotherapy in clinical trials has led to its establishment as a new pillar of cancer therapy. However, little clinical efficacy has been achieved in microsatellite stable colorectal cancer (MSS-CRC), which constitutes most CRC tumors. Here, we discuss the molecular and genetic heterogeneity of CRC. We review the immune escape mechanisms, and focus on the latest advances in immunotherapy as a treatment modality for CRC. By providing a better understanding of the tumor microenvironment (TME) and the molecular mechanisms underlying immunoevasion, this review offers an insight into developing therapeutic strategies that are effective for patients with various subsets of CRC.

KW - CTLA-4

KW - PD-1

KW - adoptive cell therapy

KW - cancer vaccines

KW - colorectal cancer

KW - immune checkpoint inhibitor

UR - https://www.scopus.com/pages/publications/85164991924

UR - https://www.scopus.com/pages/publications/85164991924#tab=citedBy

U2 - 10.1016/j.drudis.2023.103669

DO - 10.1016/j.drudis.2023.103669

M3 - Review article

C2 - 37328052

AN - SCOPUS:85164991924

SN - 1359-6446

VL - 28

JO - Drug Discovery Today

JF - Drug Discovery Today

IS - 9

M1 - 103669

ER -

Immunotherapy and immunoevasion of colorectal cancer

Abstract

UN SDGs

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this